Kymab strengthens management team
This article was originally published in Scrip
Cambridge, UK-based Kymab, a monoclonal antibody biopharmaceutical company, has named Steve Arkinstall chief scientific officer and Nigel Clark president and head of business development. Mr Arkinstall joins the company from Merck Serono where he held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of global technologies and external innovation. He succeeds Allan Bradley as CSO at Kymab. Mr Bradley, a founder of the company, will remain on the executive leadership team.
You may also be interested in...
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.
Top 30 Leaders: see the list of entrepreneurs and innovators highlighted in the third edition of In Vivo's Rising Leaders series.